This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Innovus Pharma CEO Is Interviewed By The CEOCFO Financial News Service

LA JOLLA, Calif., March 18, 2013 (GLOBE NEWSWIRE) -- Innovus Pharmaceuticals, Inc., ("Innovus Pharma") (OTCBB:INNV) today announced that Dr. Bassam Damaj, Chief Executive Officer, was recently interviewed by the CEOCFO financial news service. The interview is available at .

In the interview, Damaj described actions and plans for Innovus Pharma since he became CEO on January 22, 2013. He noted that since he took over, the mission of Innovus has changed into developing and licensing as well as acquiring and marketing pharmaceutical products in four main areas: dermatology, autoimmune, respiratory and sexual dysfunction diseases.

Damaj said that Innovus products in these areas are differentiated and unique in the sense that they are uniquely packaged and presented for better patient compliance, convenience and results.

In addition, Damaj noted that Innovus recently signed a binding term sheet with Prospector Capital Partners II for the acquisition of nine FDA-approved, prescription products from that company. The products are not yet on the market and once the transaction closes, Innovus will be working on setting up manufacturing, distribution and reimbursement, Damaj said.

Innovus also signed a second binding term sheet for the acquisition of CIRCUMserumâ„¢ for increasing sensitivity to the skin of the penis. In a use study, completed after the product was launched in 2012 in the U.S., 80% of regular users reported heightened sensations and greater sexual satisfaction.

Damaj noted that CIRCUMserumâ„¢ is expected to be especially effective in circumcised men, whose penises lose sensitivity over time without the protective foreskin, and in men with diabetes, who have a high incidence of erectile dysfunction because of neuropathy of the extremities.

The two term sheets signed in a short period are an indication of the focus and execution of Innovus management on its objectives, Damaj said.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $94.99 -0.02%
FB $99.54 -0.21%
GOOG $678.11 -0.68%
TSLA $148.25 0.18%
YHOO $26.82 -0.85%


Chart of I:DJI
DOW 16,014.38 -12.67 -0.08%
S&P 500 1,852.21 -1.23 -0.07%
NASDAQ 4,268.7630 -14.99 -0.35%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs